Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegozafermin (BIO89-100) in Severe Hypertriglyceridemia
NCT04541186Phase 2Completed
- Sponsor
- 89bio
- Start
- Sep 2020
- Primary completion
- May 2022
- Modality
- Carrier/Scaffold Proteins
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of pegozafermin in hypertriglyceridemia (5 arms), sponsored by 89bio. Primary endpoint: Percent Change From Baseline to Week 8 in Serum Triglyceride (TG). Started Sep 2020; status: completed.
02
Drugs
pegozafermin
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT04541186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541186.